Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Bezawit A Woldemeskel; Caroline C Garliss; Tihitina Y Aytenfisu; Trevor S Johnston; Andrea L Cox; Andrew H Karaba; Joel N Blankson

doi:10.1093/cid/ciac305

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Clin Infect Dis. 2022 Oct 29;75(9):1652-1654. doi: 10.1093/cid/ciac305.

Authors

Bezawit A Woldemeskel¹, Caroline C Garliss¹, Tihitina Y Aytenfisu¹, Trevor S Johnston¹, Andrea L Cox¹, Andrew H Karaba¹, Joel N Blankson¹

Affiliation

¹ Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.

Abstract

We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.

Keywords: COVID-19; Omicron; SARS-CoV-2; T cells; antibodies.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines*
COVID-19*
Humans
RNA, Messenger / genetics
SARS-CoV-2 / genetics
T-Lymphocytes
mRNA Vaccines

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Authors

Affiliation

Abstract

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding